Conferences

AASLD 2015

The Liver Meeting 2015, organised by the American Association for the Study of Liver Diseases (AASLD), took place in San Francisco, USA, from 13-17 November 2015.
New & experimental hepatitis C treatment

New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study

New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation

New & experimental hepatitis C treatment

Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection

Hepatitis C treatment

United States faces biggest burden of hepatitis C treatment costs before 2020

Hepatitis C symptoms & diagnosis

Coffee consumption linked to reduced liver fibrosis in people with HBV, HCV and NAFLD

Hepatitis C treatment

High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy

New & experimental hepatitis C treatment

Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks

Hepatitis C treatment

Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction

Drug interactions & pharmacokinetics

Study reveals potential challenges for scaling up of HCV therapy in UK

Hepatitis C treatment

Liver fibrosis improves after successful treatment for hepatitis C

New & experimental hepatitis C treatment

Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice

New & experimental hepatitis C treatment

Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C

Hepatitis B

Tenofovir during pregnancy reduces risk of mother-to-child hepatitis B virus transmission

New & experimental hepatitis C treatment

New AbbVie hepatitis C combination cures 93 to 97% with genotype 3

New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients

New & experimental hepatitis C treatment

Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment

Hepatitis C treatment

Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows

Hepatitis B

REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection

Hepatitis C symptoms & diagnosis

Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C

New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3

Hepatitis C transmission & prevention

HCV transmission during anal sex may happen without blood, study in HIV/HCV coinfected men finds

New & experimental hepatitis C treatment

Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs